ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be presenting data evaluating the response to its T cell inducing SLP therapy against SARS-CoV-2 in collaboration with the Leiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR) at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), being held in Mainz, Germany on 3-5 May, 2023.

Details of the presentation are as follows:

Presentation title: T cell inducing SLP vaccine against SARS-CoV-2 for protection of patients with spontaneous or therapy-induced B cell deficiencies

Session: Therapeutic Vaccination, New Targets New Leads, Tumor Biology & Interaction with

the Immune System

Abstract Number : 167

Presenting Author: Esmé TI van der Gracht

Date & Time: Thursday, 4 May at 3:30 pm - 6:00 pm CEST

Abstracts are published and can be accessed on the CIMT website at https://www.meeting.cimt.eu/speakers-and-program

ISA’s versatile synthetic long peptide (SLP®) immunotherapy platform is designed to elicit a strong and specific T cell immune response against a target, with the intention to clear an established infection. ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

The presentation entitled “T cell inducing SLP vaccine against SARS-CoV-2 for protection of patients with spontaneous or therapy-induced B cell deficiencies” demonstrates that ISA106 adjuvanted SLP therapy is capable of eliciting robust T cell responses in mice and reactivating robust memory T cell responses. These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection. The data confirms that further development of ISA106 is warranted to provide improved protection against SARS-CoV-2 virus-induced disease, in persons with spontaneous or therapy-induced B cell deficiencies, by inducing adequate anti-viral T cell immunity. These data further demonstrate the power of ISA’s SLP platform to activate the immune system and generate strong and broad T-cell responses against specific targets of interest.

Dr Esmé TI van der Gracht, Immunology Scientist at ISA Therapeutics, said: “We are delighted to be sharing data demonstrating the progress we are making with our SLP therapy targeting the highly transmissible and pathogenic SARS-CoV-2. The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective.”

If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at info@isa-pharma.com. For more information, please visit us at isa-pharma.com.